MAY 16, 2014 12:00 AM PDT

Sedatives Appear Effective for Treating Seizures in Children

A study published in the April 23 issue of JAMA showed that the sedative drugs diazepam (Valium) and lorazepam (Ativan) are equally effective in treating the prolonged seizures known as status epilepticusin children. The randomized, controlled study was conducted by a multi-institution team of researchers with the Pediatric Emergency Care Applied Research Network, including an expert from the Perelman School of Medicine at the University of Pennsylvania.

Medscape defines status epilepticus (SE) as a seizure that lasts more than 30 minutes. The annual incidence of convulsive SE among children in developed countries is about 20 per 100,000 people. It is a serious and often life-threatening medical emergency and requires prompt intervention.

The new study found that both medications were effective in stopping status epilepticus in more than 70 percent of cases and caused respiratory side effects in less than 20 percent of patients. Diazepam and lorazepam were administered intravenously (IV) for the treatment of prolonged seizures. Previous studies in children had suggested that lorazepam was more effective in stopping convulsions or had lower rates of breathing-related side effects.

Both medications are benzodiazepines, a class of drugs primarily used for treating anxiety. They are also effective in treating several other conditions, including seizures. Benzodiazepines are sedatives that also prevent or stop seizures by slowing down the central nervous system, making abnormal electrical activity less likely. The FDA has approved diazepam, but not lorazepam, for the treatment of prolonged seizures in children, despite the fact that many experts are advocating its use for this purpose.

"The data from this study show that both medications are equally effective and safe and may lead to expanded options for selecting drugs that are stable for use in emergency settings or resource poor environments," said Jill M. Barenm MD, chair of the Department of Emergency Medicine at Penn and the study's senior author. "Our results can also be used to support efforts to obtain FDA approval for lorazepam for treating children who suffer prolonged seizures."

Baren also noted that the current study was designed to improve upon the limitations of previous studies. Earlier "off-patent" comparisons were retrospective, from single hospitals, and had small sample sizes, thus limiting the ability to generalize. Nonetheless, retrospective studies cannot ensure that dosing was given in a standardized manner or that patients were randomly assigned to receive one medication or the other, raising the possibility of extraneous variables contributing to the findings.

The study results have important implications for both pre-hospital (administered at home or in school, for example) and emergency department care. First, they support the choice of either diazepam or lorazepam as a first choice for pediatric status epilepticus. Second, because diazepam can be stored without refrigeration, it could be more convenient for use in certain pre-hospital settings such as by EMS personnel. "It may be that logistic considerations, rather than concerns about efficacy or safety, should influence the choice," said Baren.

The new JAMA study is the largest prospective randomized trial comparing intravenous lorazepam to diazepam for the treatment of status epilepticus in children. It assessed 273 patients, aged three months to 17 years, from 11 large, geographically diverse pediatric academic hospitals in the US and Canada; 140 were randomized to diazepam and 133 to lorazepam. Prior pre-hospital care was controlled for by excluding all patients who had received a benzodiazepine in the previous seven days, allowing for an uncontaminated examination of efficacy and safety.

The study was a large, double-blinded, prospective, randomized, controlled clinical trial in children presenting to emergency departments in 11 hospitals across the U.S. during generalized convulsive status epilepticus. It was funded by the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (HHSN275201100017C).
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
SEP 05, 2018
Cardiology
SEP 05, 2018
Stroke Doubles Risk of Dementia
History or recent stroke can double the risk of dementia....
SEP 13, 2018
Neuroscience
SEP 13, 2018
Can Nerve Stimulation Treat Depression?
Depression is a significant mental health disorder that thousands of people suffer from on a daily basis. According to the CDC, the prevalence of depressio...
OCT 01, 2018
Videos
OCT 01, 2018
Is Bigger Better?
Bigger is better, right? If you’re trying to insult someone you might call them a “pea brain” or tell them they have a “bird brain,...
NOV 05, 2018
Neuroscience
NOV 05, 2018
Stress: Men Vs. Women
Undersatnding the gender specific differences in response to stress...
NOV 07, 2018
Immunology
NOV 07, 2018
Inflammation Can Steal Your Sleep
A link between inflammation and the circadian rhythm has been determined in mouse models. High-fat-diets may be the cause....
NOV 18, 2018
Neuroscience
NOV 18, 2018
How does the brain know when we are full?
Feeling full or satiation is conveyed to the brain by the gut hormones via the enteric neuronal afferents and the endocrine feedback pathways....
Loading Comments...